Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.
ALK Inhibitor Comparison and CNS Penetration
Key Themes:
Notable Insights:
Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
June 19th 2025Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Read More